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Effects of nateglinide and rosiglitazone 
on pancreatic alpha- and beta-cells, GLP-1 
secretion and inflammatory markers in patients 
with type 2 diabetes: randomized crossover 
clinical study
Glauce Cordeiro Ulhôa Tostes* , Maria Rosário Cunha, Rosa Tsumeshiro Fukui, Márcia Regina Silva Correia, 
Dalva Marreiro Rocha, Rosa Ferreira dos Santos and Maria Elizabeth Rossi da Silva
Abstract 
Background: To compare the effects of nateglinide and rosiglitazone on inflammatory markers, GLP-1 levels and 
metabolic profile in patients with type 2 diabetes (DM2).
Methods: A prospective study was performed in 20 patients with DM2, mean age 51.82 ± 8.05 years, previously 
treated with dietary intervention. Participants were randomized into rosiglitazone (4–8 mg/day) or nateglinide (120 mg 
3 times a day) therapy. After 4 months, the patients were crossed-over with 8 weeks washout period to the alternative 
treatment for an additional 4-month period on similar dosage schedule. The following variables were assessed before 
and after 4 months of each treatment period: (1) a test with a standardized 500 calories meal for 5 h including frequent 
measurements of glucose, insulin, glucagon, proinsulin, GLP-1, free fat acids (FFA), and triglycerides levels was obtained. 
The lipid profile and HbA1 levels were measured at fasting. (2) Haemostatic and inflammatory markers: platelet aggre-
gation, fibrinogen, PAI-1 activity, C reactive protein (CRP), IL-6, TNF-α, leptin, sICAM and TGFβ levels.
Results: Both therapy decreased blood glucose levels under the postprandial curve but neither affected glucagon 
and GLP-1 levels. Nateglinide was associated with higher insulin and pro-insulin secretion, but similar pro-insulin/insu-
lin ratio when compared with rosiglitazone. Only rosiglitazone decreased Homa β, PAI-1 activity, CRP, fibrinogen, TGFβ, 
FFA and triglyceride levels.
Conclusions: Nateglinide and rosiglitazone were effective in improving glucose and lipid profile and β cell function, 
but rosiglitazone afforded a better anti-inflammatory effect. No drug restored alpha cell sensitivity or changed GLP-1 
levels. Maintenance of haemostatic factors, inflammatory factors and glucagon levels can be related to the continu-
ously worsening of cardiovascular function and glucose control observed in DM2.
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Background
Cardiovascular disease is the leading cause of mortality 
in patients with type 2 diabetes mellitus. The rigorous 
control of glycemia can delay but not prevent vascular 
complications, which are probably related to many other 
poorly controlled atherogenic factors, such as obesity, 
hypertension, hyperlipidemia, insulin resistance, oxida-
tive stress, accelerated aging, disturbances in coagulation 
and fibrinolysis [1].
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Although metformin has been confirmed as the first 
line option to treat diabetes, troublesome gastrointestinal 
intolerance sometimes precludes its use [2].
Rosiglitazone and nateglinide are drugs that differ in 
their primary mechanism of action and have been previ-
ously considered in type 2 diabetes treatment.
The thiazolidinedione rosiglitazone, a peroxisome 
proliferator activated receptor gamma (PPARγ) agonist, 
is an insulin sensitizing agent that improves glycaemic 
control and a variety of other metabolic disturbances in 
patients with type 2 diabetes. However, besides weight 
gain, it promoted fluid retention and heart failure [3–5]. 
The increased risk of acute myocardial infarction and a 
trend towards increased mortality with the drug brought 
concern about the safety of rosiglitazone, prompting its 
withdrawn of the market.
Another alternative option to therapy can be the insu-
lin secretagogue nateglinide [6] that is a derivative of 
phenylalanine and structurally distinct of sulphonylu-
reas, which also had raised concern over their potential 
adverse effects in the event of ischemic heart disease. 
Nateglinide’s interaction with sulpnhonylurea receptor 
(SUR1), a subunit of the ATP sensitive potassion chan-
nel (KATP) on plasma membrane is fleeting, favoring a 
rapid onset and short duration of insulin secretion, pro-
viding post-prandial glucose control with less hypogly-
cemia and weight gain [6, 7]. The promotion of glucagon 
like peptide 1-(GLP-1) release from intestinal L cells 
may be another important mechanism by which nateg-
linide restores early-phase insulin secretion and regu-
lates postprandial glucose metabolism [8]. However, this 
effect could be due to improvement in glucose levels and 
deserves confirmation.
Furthermore, nateglinide has little binding to the vas-
cular muscle and cardiac SUR2 receptors [9] suggesting 
that it could be a good and safe option to new diagnosed 
type 2 diabetes. However there are few and contradictory 
reports of nateglinide effects on cardiovascular function 
[10–14] and inflammatory markers, many of them com-
paring nateglinide to placebo, difficulting to separate 
the impact of improvement of glucose control on the 
obtained results. Also, the influence of nateglinide on 
glucagon secretion is poorly known.
To the best knowledge of nateglinide effects we con-
ducted this study comparing the effects of nateglinide 
with rosiglitazone on glucose and lipid profile, but also 
on several parameters still not well characterized like 
pancreatic alpha and beta cells response to diet, the 
incretin hormone GLP-1, inflammatory markers, and 
haemostatic factors. The purpose of the current study 
was also to ascertain whether anti-diabetic agents with 
different primary mechanisms of action targeting the two 
main pathophysiological defects of type 2 diabetes would 
have different effects on these parameters and if they 
were independent of glucose control.
Methods
Subjects
A prospective study was performed in 22 patients with 
type 2 diabetes according to ADA criteria [2], 16 F:6 M, 
mean age 51.2 ± 8.05 years, IMC = 27.9 kg/m2 and dia-
betes duration of 1.9 ± 2.1 years that were treated with 
dietary intervention in the previous 2 months.
Study design
Participants were randomly assigned to receive either 
nateglinide (nateglinide group) or rosiglitazone (rosigli-
tazone group). The rosiglitazone dosage was titrated 
in order to achieve fasting glucose levels lower than 
7.0  mmol/L using domiciliary capillary glucose meas-
urements. Nateglinide was administrated in a fixed dose 
three times a day. After 4  months, the patients were 
crossed-over after 8-week washout period to the alter-
native treatment for an additional 4-month period on a 
similar dosage schedule. Subjects were followed on an 
outpatient basis every 1–2  weeks for drug and weight-
maintaining diet adjustments throughout the study 
period. The clinical characteristics of the patients are 
depicted in Table 1. At the time of entry, a complete his-
tory, physical examination, and laboratory evaluation 
including urinalysis, renal, hepatic and thyroid function 
tests, serum lipid and electrolytes levels and ECG were 
obtained for all subjects. None of the patients exercised 
on a regular basis. Exclusion criteria included any severe 
concomitant illness, uncontrolled hypertension (blood 
pressure > 190 × 120 mmHg), marked dyslipidemia and 
use of hypolipemic and anticoagulant medications. No 
subjects had any acute concurrent illness.
The Medical Ethics Committee of Hospital das Clínicas 
da Faculdade de Medicina da Universidade de São Paulo 
approved the study protocol and all subjects gave written 
informed consent.
Study protocol
The patients were instructed to follow similar food intake 
and to abstain from use of tobacco, alcohol, coffee and 
any physical activity 24-h before the test days. The fol-
lowing procedures were performed before (basal values) 
and after each 4 months treatment period (nateglinide or 
rosiglitazone groups): (1) hormonal and metabolic deter-
minations: a test with a standardized 500-kcal mixed 
breakfast tolerance test (60 % carbohydrate, 20 % fat and 
20 % protein) for 5 h including frequent plasma or serum 
measurements (at times 0, 15, 30, 45, 60, 120, 180, 240 
and 300  min) of glucose, insulin, glucagon, proinsulin, 
GLP-1, free fat acids (FFA), and triglycerides levels was 
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performed after 12 h fasting. The fasting lipid profile and 
HbA1 levels were also measured. (2) Haemostatic and 
inflammatory markers: fasting blood fibrinogen, plas-
minogen activator inhibitor (PAI-1) activity, C reactive 
protein (CRP), Interleukin 6 (IL-6), tumor necrosis fac-
tor alfa (TNFα), leptin, intercellular adhesion molecule-1 
(sICAM), transforming growth factor beta (TGFβ) levels 
and platelet aggregation. (3) Cardiovascular evaluation: 
24-h blood pressure monitoring.
Biochemical and hormonal analysis
Glucose levels were determined by the glucose oxidase/
peroxidase method (Labtest, São Paulo, Brazil) and gly-
cated hemoglobin (HbA1c) by HPLC (National Glyco 
Hemoglobin Standardization Program, USA. Triglycer-
ide levels were measured by the lipase/glycerol kinase 
method (Labtest, São Paulo, Brazil) and total cholesterol 
(total-C) by the cholesterol oxidase/peroxidase method. 
HDL-cholesterol (HDL-C) was separated using the phos-
photungstic acid/Mg2+ method and measured by oxidase/
peroxidase method. LDL-cholesterol (LDL-C) was esti-
mated by Friedewald equation. Free fat acids (FFA) were 
measured utilizing enzymatic colorimetric method (Wako 
Chemicals USA, INC). A double-antibody radioimmu-
noassay was used to measurements of. insulin, proinsu-
lin, glucagon (Linco Research, St. Louis, MO, USA) and 
total GLP-1 (Millipore Corporation. Billerica, MA) Intra-
assay and interassay CVs for hormonal analyses were 6.8 
and 9.6  % for insulin; 4.4 and 6.5  % for glucagon; 5 and 
5.3 % for proinsulin and <5 % for GLP-1. Circulating levels 
of Il-6, TNF-α, leptina, sICAM, TGF beta and CRP were 
measured with high sensitivity ELISA kits (R&D Systems). 
The samples of each patient were analyzed in the same 
assay. Intra-assay CV were  <8  % for Il-6, TNF-alfa and 
leptin and <4.5 % for sICAM, TGF-β and CRP.
Haemostatic factors were measured using the same 
assay for each patient. Fibrinogen was determined by 
the CLAUSS method [15] with Fibriquick Assay, Sigma, 
USA. The plasminogen activator inhibitor (PAI-1) activ-
itiy was determined by quantitative assays (Chromolize™ 
PAI-1, Biopool, Umea, Sweden); The intra-assay CVs 
were 8 and 3.7  %, respectively. Platelet aggregation was 
also determined [16].
Systolic and diastolic blood pressure (BP) values were 
assessed by 24-h ambulatory BP monitoring in all patients 
every 20  min from 8.00 a.m. to midnight, and every 
30 min from midnight to 8.00 a.m. in the following day.
All analyses were done in duplicate.
Statistical analysis
Numerical data were reported as mean and standard 
deviation or median and percentile. Differences (95  % 
Table 1 Clinical and biochemical characteristics of 20 patients with type 2 diabetes at baseline and after 4 months of nat-
eglinide or rosiglitazone therapy
Wilcoxon matched pairs tests were performed to compare the differences before and after the 4 months of therapy for each group
Italic values indicate statistical significance at p < 0.05
CRP reactive protein, HDL-c HDL cholesterol, LDL-c LDL-cholesterol, PAI-1 plasminogen activator inhibitor, sICAM-1 intercellular adhesion molecule-1, TGFβ 
transforming growth factor beta, TNFα tumor necrosis factor alfa, Total-c total cholesterol
Variables Baseline Nateglinide p Baseline Rosiglitazone p
After 4 months After 4 months
Median (25th–75th) Median (25th–75th) Median (25th–75th) Median (25th–75th)
Body weight (kg) 67.9 (64.1–81.0) 70.0 (64.5–78.0) 0.073 69.0 (63.9–77.0) 68.9 63.6–77.9 0.984
Hba1c (%) 7.45 (7.0–8.3) 6.65 (5.7–7.8) 0.032 7.2 (6.8–8.1) 6.6 5.5–7.5 0.036
Homa Beta 40.7 (28.8–52.0) 51.3 (28.7–73.0) 0.126 33.6 (26.8–59.0) 51.6 30.9–69.9 0.005
Total-c (mg/dL) 223.5 (178.5–235.3) 194.0 (182.0–213.0) 0.036 213.0 (184.0–230.0) 211.0 201.0–245.0 0.277
HDL-c (mg/dL) 44.5 (37.8–57–8) 44.5 (34.0–55.0) 0.360 45.0 (40.0–56.0) 48.0 38.0–55.0 0.347
LDL-c (mg/dL) 144.0 (111.0–153.5) 131.5 (109.5–142.0) 0.145 152.0 (106.0–157.0) 142.0 124.0–168.0 0.355
CRP (mg/L) 5.2 (1.87–8.91) 3.79 (1.63–7.64) 0.052 4.16 (2.23–8.37) 3.10 (0.87–6.34) 0.042
TGF β (pg/mL) 44.1 (34.2–51.1) 45.3 (32.2–49.4) 0.247 42.7 (37.8–47.9) 38.3 32.0–45.8 0.001
Interleukin-6 (pg/mL) 2.54 (1.45–5.66) 2.37 (1.16–3.53) 0.108 2.71 (1.46–4.17) 2.00 1.42–3.89 0.520
leptina (ng/mL) 14.9 (7.6–21.0) 17.9 (10.0–20.8) 0.808 13.1 (6.0–19.3) 16.2 7.0–24.1 0.199
sICAM-1 (ng/mL) 233.8 (179.7–261.5) 214.9 (186.7–263.3) 0.391 223.6 (171.3–241.6) 218.0 173.8–246.0 0.573
TNF α (pg/mL) 1.71 (1.18–2.50) 1.52 (1.08–2.91) 0.235 1.49 (1.23–2.09) 1.43 1.18–2.18 0.760
fibrinogen (mg/dL) 316.0 (276.8–375.0) 336.5 (297.8–357–5) 0.433 337.0 (296–397) 322.0 (262.5–363.8) 0.024
PA-1 activity (UI/mL) 27.7 (14.4–43.8) 24.7 (14.7–40.3) 0.55 15.9 (11.6–40.0) 12.7 8.0–19.0 0.040
platelet aggregation 90.3 (80.1–96.0) 90.0 (81.0–92.6) 0.601 89.0 (76.4–94.5) 90.9 76.0–95.0 0.643
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CI) between treatment groups were initially tested for 
treatment-time interaction [17] and then compared 
by Mann–Whitney tests. Baseline and post-treatment 
differences between the nateglinide and rosiglitazone 
groups were compared by Mann–Whitney tests. Wil-
coxon matched pairs tests were performed to compare 
the differences in clinical and biochemical measurements 
for each group before and after the four months of ther-
apy. The responses to the standardized 500-kcal mixed 
breakfast tolerance test were analyzed by the area under 
the curve using the trapezoidal rule and by Wilcoxon test 
for every time for the 5 h duration. Graphical representa-
tions are as mean and standard error. Statistical analysis 
was performed using Prisma software (version 10.1, SPSS 
Inc., Chicago). In all cases a p < 0.05 was considered sta-
tistically significant.
Results and discussion
Results
No treatment period interaction effect was demon-
strated; hence the values from each treatment periods 
were analyzed together. Two patients that started with 
rosiglitazone did not finished the nateglinide period due 
to a worsening in diabetes control. The final analysis 
comprised 20 patients on rosiglitazone and 20 patients 
on nateglinide.
Anthropometric, biochemical, hormonal and haemostatic 
factors measurements
There were no significant differences (p > 0.05) in baseline 
clinical and biochemical measurements of those patients 
randomized to nateglinide or rosiglitazone (Table 1).
HbA1 levels fell (nateglinide-p =  0.032; rosiglitazone-
p = 0.036) equally in both treatment groups (p = 0.91). 
Proportions of patients achieving an endpoint HbA1c 
of <7 % were similar for nateglinide (60 %) and rosiglita-
zone (75 %) groups p = 0.5.
The total and incremental areas under the curve (AUC) 
during the standardized diet tolerance test were ana-
lyzed. Both treatments caused a similar decrease in total 
and incremental prandial glucose AUCs (Table 2).
However, there were significant between-treatment 
difference for the following parameters: rosiglitazone 
decreased glucose levels significantly at all times of the 
curve, including fasting, whereas nateglinide decreased 
mainly the post prandial glucose levels (Fig. 1).
The initial insulin response to a meal was anticipated 
and augmented with nateglinide treatment (Fig.  1). 
Nateglinide also increased the prandial insulin (total 
and incremental AUC) and pro-insulin (incremental 
AUC) responses and the insulinogenic index, whereas 
decreased both glucose/insulin and proinsulin/insulin 
ratios (total and incremental) Table 2.
On the contrary, rosiglitazone decreased insulin (incre-
mental) and proinsulin (total) AUCs and increased HOMA 
beta. Comparing both groups, rosiglitazone treatment 
caused lower total (p = 0.012) and incremental (p = 0.005) 
insulin AUC, incremental (p  =  0.023) pro-insulin AUC 
and insulinogenic index (p = 0.002), but higher incremen-
tal glucose/insulin ratio AUC (p = 0.042) Table 2.
Considering lipids, Rosiglitazone decrease prandial 
FFA (total AUC) and triglyceride (incremental AUC) 
(Table  2; Fig.  2), whereas nateglinide decreased fasting 
LDL-cholesterol levels (Table 1).
Only rosiglitazone decreased PAI-1 activity, fibrinogen, 
PCR and TGF-β levels (Table 1).
There was no significant effect of either of the therapies 
on glucagon or GLP-1 AUCs (Table  2; Figs.  1, 2) or on 
HOMA IR, fasting IL-6, leptin, s-ICAM, TNF alpha and 
HDL cholesterol levels (Table 1).
Weight and waist/hip ratio did not change after 
4 months of both treatments.
Twenty‑four hour ambulatory blood pressure monitoring
Neither therapy changed 24-h systolic and diastolic blood 
pressure measurements.
Discussions
This clinical, prospective, randomized, crossover study 
compared the effects of two different classes of drugs 
(rosiglitazone, an insulin sensitizer, and nateglinide, 
an insulin secretagogue) in type 2 diabetes patient. We 
evaluated the same patient under basal conditions, i.e., 
while hyperglycemic without medications, and again 
after 4  months of treatment with nateglinide or rosigli-
tazone. The major aims of this strategy was to minimize 
the influence of metabolic control on the specific drug 
effect. Despite similar improvements on glucose control, 
changes on lipid profile, insulin response and inflamma-
tory markers were different with therapies.
Both treatment groups achieved similar and signifi-
cant mean decreases from baseline in plasma glucose and 
fasting HbA1c levels. Proportions of patients achieving 
an endpoint HbA1c of <7 % were similar for nateglinide 
and rosiglitazone groups. Initial insulin response to the 
5  h standardized 500 calories breakfast was augmented 
only with nateglinide treatment. The higher insulin and 
proinsulin levels, observed during nateglinide therapy, 
are in line with reports of its stimulatory effects on beta 
cells function, favoring a quick onset and short dura-
tion of insulin secretion, contrasting with the rosigli-
tazone’s sparing effects on beta cells function [3, 6, 7]. 
As expected, nateglinide anticipated the insulin peak 
response, improving mainly post-prandial glucose levels 
whereas rosiglitazone decreased glucose levels signifi-
cantly at all times of the curve (Fig. 1).
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Similar results were seen with proinsulin levels during 
the meal test: increased with nateglinide and decreased 
with rosiglitazone.
So, both treatment affected beta cell function. Despite 
increasing insulin secretion, the pro-insulin/insulin area 
under the curve ratio during the 5  h of the breakfast 
decreased during nateglinide treatment, suggesting that 
it improved previous secretory dysfunction of beta cells, 
contrasting with the worsening in beta cells function 
usually reported to sulphonylureas [18]. The increase in 
insulin secretion could not be accounted for by changes 
in body weight—it was unaffected in both groups, prob-
ably because of the short duration of post prandial insu-
lin secretion during nateglinide therapy, the frequent 
ambulatory visits and nutritional counseling of the 
patients. There was no complains of hypoglycemia with 
both treatments.
Rosiglitazone also improved beta cells function, 
attested by the increase in HOMA-B value. Despite caus-
ing lower prandial insulin response, rosiglitazone kept 
total and incremental glucose AUC at similar levels when 
compared with nateglinide.
Overall changes on plasma lipids levels were different 
with therapies. Only rosiglitazone decreased post-pran-
dial FFA and of triglycerides levels, both of which prob-
ably accounted to the observed amelioration of beta cell 
function (HOMA-B) and of insulin resistance, reflecting 
on the glucose-lowering action of rosiglitazone.
Table 2 Test with a standardized 500 calories mixed breakfast for 5 h: metabolic profile
Wilcoxon matched pairs tests were performed to compare the differences for each group before and after the 4 months of therapy
Italic values indicate statistical significance at p < 0.05
GLP-1 glucagon like peptide-1
Areas 
under the 
curve
Baseline Nateglinide p Baseline Rosiglitazone p
After 4 months After 4 months
Median (25th–75th) Median (25th–75th) Median (25th–75th) Median (25th–75th)
Glucose (mg/dL × min)
 Total 52,455 (4668–60,140) 40,245 (35,468–48,125) 0.001 47,340 (41,770–57,240) 43,670 37,820–51,550 0.005
 Incremental 11,955 (9251–15,523) 9241 (8004–12,805) 0.005 12,620 (8216–16,070) 11,070 (7595–12,330) 0.035
Insulin (U/mL × min)
 Total 6454 (5561–9922) 9220 (5807–16,340) 0.008 6992 (5023–8584) 6120 4213–7590 0.099
 Incremental 4107 (3277–6917) 6442 (4255–12,038) 0.006 4051 (2566–5324) 3208 2658–4756 0.049
Proinsulin (pM × min)
 Total 15,460 (9841–27,613) 16,020 (10,705–30,395) 0.135 12,470 (10,230–24,500) 11,730 7823–18,830 0.033
 Incremental 8100 (5601–12,305) 9915 (6203–18,713) 0.03 6668 (5505–9680) 6263 4706–9455 0.107
Glucagon (pg/mL × min)
 Total 23,535 (21,070–27,958) 22,160 (19,023–27,795) 0.455 21,460 (16,470–27,140) 24,060 19,500–25,740 0.520
 Incremental 3565 (2739–5480) 3094 (2119–5031) 0.351 3647 (2039–4770) 3268 2344–4302 0.748
GLP1 (pM × min)
 Total 46,995 (36,463–53,685) 48,660 (36,773–56,098) 0.179 42,890 (32,640–56,060) 42,390 37,710–47,390 0.872
 Incremental 4140 (3125–5464) 4454 (2680–6693) 1.000 3840 (2065–6469) 4171 2491–5602 0.687
Triglicerides (mg/dL × min)
 Total 43,500 (30,578–64,283) 46,375 (35,430–61,880) 0.737 42,060 (32,320–54,510) 40,350 30,480–59,240 0.717
 Incremental 9353 (5474–15,643) 11,120 (9132–16,548) 0.218 10,080 (6660–13,170) 9106 3945–10,580 0.044
Free fat acids (mEq/L ×min)
 Total 85.4 (75.6–113.6) 98.0 (81.5–119.1) 0.263 105.9 (79.1–113.3) 70.5 52.7–80.0 0.007
Glucose/insulin ratio
 Total 6.55 (5.27–10.01) 4.37 (2.86–6.62) 0.001 7.32 (5.93–10.61) 6.87 5.62–10.39 0.629
 Incremental 2.57 (1.72–3.98) 1.69 (0.77–2.31) 0.001 2.70 (2.26–5.07) 2.78 1.48–4.45 0.398
Proinsulin/insulin ratio
 Total 2.47 (1.37–3.11) 1.65 (1.37–2.17) 0.028 2.2 (1.64–3.2) 2.06 1.36–2.44 0.107
 Incremental 1.93 (1.21–2.43) 1.51 (1.20–1.82) 0.044 1.84 (1.44–2.40) 1.62 1.37–2.42 0.469
Insulinogenic index
48.6 (29.1–80.6) 205.7 (80.0–541.1) 0.002 41.8 (26.3–101.9) 65.1 47.8–91.7 0.355
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Fig. 1 Test with a standardized 500 calories mixed breakfast for 5 h: blood glucose, insulin, proinsulin and glucagon levels. N1 and N2 before and 
after 4 months of nateglinide therapy. R1 and R2 before and after 4 months of rosiglitazone therapy. Hatched area data of normal controls. Data were 
analyzed by the area under the curve using the trapezoidal rule and by Wilcoxon test for every time for the 5 h duration (p < 0.05)
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By the other side, nateglinide decreased fasting choles-
terol levels, that were lower than with rosiglitazone treat-
ment (p = 0.04).
Small changes in lipid metabolism were expected, and 
previous reports have also been light [3–6]. The near 
normal triglyceride and cholesterol levels of our patients 
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Fig. 2 Test with a standardized 500 calories mixed breakfast for 5 h: blood glucagon like peptide-1(GLP-1), free fat acids (FFA) and triglyceride levels. 
N1 and N2 before and after 4 months of nateglinide therapy. R1 and R2 before and after 4 months of rosiglitazone therapy. Hatched area: data of 
normal controls. Data were analyzed by the area under the curve using the trapezoidal rule and by Wilcoxon test for every time for the 5 h duration 
(p < 0.05)
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prior both therapies was probably a factor influencing 
these modest results. However, neither the increase in 
insulin production nor the increase in insulin sensitivity 
were able to decrease fasting or post-prandial glucagon 
levels, confirming that both the inherent effects of each 
drugs, allied to the decrease in gluco and lipotoxicity 
were insufficient to restore alfa cells sensitivity to glucose 
and insulin levels, favoring the progression of diabetes.
Besides improvements on plasma FFA levels and 
HOMA beta, rosiglitazone treatment decreased CRP, 
TGF beta and fibrinogen levels and PAI-1 activity. These 
data suggest drug specific effects, not dependent on ame-
lioration of the metabolic milieu.
Inflammatory markers and other haemostatic factor 
(IL-6, TNF alpha, leptin, s-ICAM, platelet aggregation) 
were unaffected by both treatment, despite the great 
improvement in glucose profile, Such persistence in 
inflammation is probably implicated in the poor reduc-
tion in cardiovascular disease despite glucose control in 
type 2 diabetes patients [19].
No changes were observed in GLP-1 levels during 
both therapies. A reduced incretin effect is a well-known 
characteristic of patients with type 2 diabetes. Impaired 
release of glucagon-like peptide-1 (GLP-1) has been 
reported to be at least partly involved in impairment of 
early-phase insulin secretion after food intake and post-
prandial hyperglycemia and hyperlipidemia [20].
High concentrations of several antidiabetic drug classes, 
namely thiazolidinediones, sulphonylureas, meglitinides 
and morphilinoguanides have been reported to inhibit the 
DPP-IV enzyme, being nateglinide the strongest inhibitor. 
So, besides its effect as a beta-cell K-ATP channel inhibi-
tor [6, 7], nateglinide was reported to act as a prandial 
insulin-releasing agent, both by inhibiting GLP-1 degra-
dation [21, 22], and by increasing GLP-1 secretion [8] sec-
ondary to the increase of intracellular calcium.
We did not confirm these data in our study.
There was no change in blood pressure. Nateglinide, 
probably due to its little binding to the vascular mus-
cle and cardiac SUR2 receptors [9], was not expected 
to change blood pressure levels. Overall assessment of 
safety demonstrated that both drugs were well tolerated, 
and there were no significant side effects or severe hypo-
glycemic episodes.
Although metformin has been confirmed as the first 
line option to treat diabetes, troublesome gastrointes-
tinal intolerance sometimes precludes its use [2]. Thus, 
glinide remains an important adjuvant for recent onset 
T2D patients. When compared with rosiglitazone, nateg-
linide achieved similar efficacy in improving glucose con-
trol. Although rosiglitazone had a sparing effect on beta 
cell function and decrease FFA, triglycerides and PAI-1 
levels, it was recently excluded from the marked due to 
an increase in cardiovascular disease. Despite leading to 
more insulin secretion, nateglinide did not worsen body 
weight or beta cell function, measured by the pro-insulin/
insulin ratio. Long term studies are needed to ascertain 
whether it can prevent beta cell exhaustion or apoptosis.
Conclusions
In patients with type 2 diabetes inadequately controlled 
by dietary therapy, nateglinide and rosiglitazone resulted 
in similar overall improvements in glucose control and 
beta cell function. In addition, nateglinide reduced total 
cholesterol levels and rosiglitazone reduced post-pran-
dial FFA and triglycerides levels and some inflammatory 
markers. Despite different mechanisms of action nether 
drug changed GLP-1 levels or previous secretory dys-
function of alpha cells. Maintenance of inflammatory 
markers, haemostatic factors and glucagon levels can be 
related to the continuously worsening of cardiovascular 
function and glucose control observed in DM2.
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